LP
IONS icon

LMR Partners’s Ionis Pharmaceuticals IONS Stock Holding History

LMR Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.08M Hold
51,400
– – 0.02% 711
2026
Q1 		$3.86M Buy
51,400
+31,400
+157% +$2.48M 0.01% 713
2025
Q4 		$1.58M Buy
+20,000
New +$1.51M ﹤0.01% 871

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LMR Partners's IONS Position: Q2 2026 in Review

LMR Partners increased its Ionis Pharmaceuticals (IONS) stake by 105% in Q2 2026, buying an estimated $1.19M and bringing the position to 30,800 shares worth $2.44M. The position accounts for 0.01% of the portfolio, ranked #843.

LMR Partners first reported a position in IONS in Q3 2016 and has held it in 8 quarters since. The position peaked at $5.3M in Q3 2016. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • LMR Partners held 30,800 shares of Ionis Pharmaceuticals worth $2.44M as of Q2 2026.
  • LMR Partners bought 15,800 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
  • Ionis Pharmaceuticals made up 0.01% of LMR Partners's portfolio in Q2 2026, its #843 holding.
  • LMR Partners first reported a position in Ionis Pharmaceuticals in Q3 2016 and has held it in 8 quarters since.
  • LMR Partners's Ionis Pharmaceuticals position peaked at $5.3M in Q3 2016.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.